influenza haemagglutinin vaccine

The influenza haemagglutinin vaccine in this context refers to a standard influenza vaccine containing haemagglutinin as its primary immunogenic component, which was investigated as a pre-operative immunostimulatory intervention. In a randomized clinical trial conducted at Charité - Universitätsmedizin Berlin, the vaccine was administered to patients with upper aerodigestive tract cancer undergoing surgery. The study aimed to mitigate surgery-induced immunosuppression and reduce post-operative infection rates by stimulating the immune system, specifically targeting monocytic HLA-DR (Human Leukocyte Antigen - DR) expression as a marker of immune competence. However, the trial results indicated that the vaccine did not significantly prevent the downregulation of HLA-DR expression or reduce post-operative infection rates compared to placebo in this perioperative context.

Other names

influenza vaccinehaemagglutinin vaccine